{"id":"gsk2340272a","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TYK2 is a non-receptor tyrosine kinase that plays a critical role in signal transduction downstream of type I and type III interferons and IL-23 signaling. By selectively inhibiting TYK2, GSK2340272A reduces the activation and differentiation of pro-inflammatory immune cells, particularly Th17 cells, thereby dampening pathogenic immune responses in autoimmune and inflammatory conditions.","oneSentence":"GSK2340272A is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:39.324Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT00968539","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":130},{"nctId":"NCT00989287","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-07","conditions":"Influenza","enrollment":131},{"nctId":"NCT00972517","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-29","conditions":"Influenza","enrollment":245},{"nctId":"NCT00968526","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":240},{"nctId":"NCT00975884","phase":"PHASE3","title":"Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-14","conditions":"Influenza","enrollment":312},{"nctId":"NCT00971321","phase":"PHASE2","title":"Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":157},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT00992511","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-14","conditions":"Influenza","enrollment":300},{"nctId":"NCT00989612","phase":"PHASE2","title":"Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":100},{"nctId":"NCT00951041","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-08-11","conditions":"Influenza","enrollment":130},{"nctId":"NCT01014091","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-12-01","conditions":"Influenza","enrollment":60},{"nctId":"NCT01161160","phase":"PHASE2","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Influenza","enrollment":209},{"nctId":"NCT00968890","phase":"PHASE2","title":"Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-12","conditions":"Influenza","enrollment":168},{"nctId":"NCT00971425","phase":"PHASE3","title":"Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":145},{"nctId":"NCT00979407","phase":"PHASE3","title":"Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-12","conditions":"Influenza","enrollment":336},{"nctId":"NCT00964158","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":210},{"nctId":"NCT00996853","phase":"","title":"Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-31","conditions":"Influenza","enrollment":9206}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK2340272A","genericName":"GSK2340272A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK2340272A is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases. Used for Psoriasis, Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}